Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential.

Naber SK, Kundu S, Kuntz KM, Dotson WD, Williams MS, Zauber AG, Calonge N, Zallen DT, Ganiats TG, Webber EM, Goddard KAB, Henrikson NB, van Ballegooijen M, Janssens ACJW, Lansdorp-Vogelaar I.

JNCI Cancer Spectr. 2019 Oct 14;4(1):pkz086. doi: 10.1093/jncics/pkz086. eCollection 2020 Feb.

2.

Optimizing Management of Patients with Barrett's Esophagus and Low-grade or No Dysplasia Based On Comparative Modeling: Optimizing Barrett's esophagus management.

Omidvari AH, Ali A, Hazelton WD, Kroep S, Lee M, Naber SK, Lauren BN, Ostvar S, Richmond E, Kong CY, Rubenstein JH, Lansdorp-Vogelaar I, Luebeck G, Hur C, Inadomi J.

Clin Gastroenterol Hepatol. 2019 Dec 6. pii: S1542-3565(19)31398-9. doi: 10.1016/j.cgh.2019.11.058. [Epub ahead of print]

PMID:
31816445
3.

Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.

Cenin DR, Naber SK, de Weerdt AC, Jenkins MA, Preen DB, Ee HC, O'Leary PC, Lansdorp-Vogelaar I.

Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):10-21. doi: 10.1158/1055-9965.EPI-18-1123. Epub 2019 Nov 20.

PMID:
31748260
4.

Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases.

Peterse EFP, Naber SK, Daly C, Pollett A, Paszat LF, Spaander MCW, Aronson M, Gryfe R, Rabeneck L, Lansdorp-Vogelaar I, Baxter NN.

Clin Gastroenterol Hepatol. 2019 Oct 17. pii: S1542-3565(19)31165-6. doi: 10.1016/j.cgh.2019.10.021. [Epub ahead of print]

PMID:
31629885
5.

Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.

Naber SK, Knudsen AB, Zauber AG, Rutter CM, Fischer SE, Pabiniak CJ, Soto B, Kuntz KM, Lansdorp-Vogelaar I.

PLoS One. 2019 Sep 4;14(9):e0220234. doi: 10.1371/journal.pone.0220234. eCollection 2019.

6.

Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.

Buskermolen M, Gini A, Naber SK, Toes-Zoutendijk E, de Koning HJ, Lansdorp-Vogelaar I.

Med Decis Making. 2018 Nov;38(8):917-929. doi: 10.1177/0272989X18806497. Epub 2018 Oct 20.

7.

The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study.

Matthijsse SM, Naber SK, Hontelez JAC, Bakker R, van Ballegooijen M, Lansdorp-Vogelaar I, de Kok IMCM, de Koning HJ, van Rosmalen J, de Vlas SJ.

PLoS One. 2018 Sep 4;13(9):e0202924. doi: 10.1371/journal.pone.0202924. eCollection 2018.

8.

Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.

Cenin DR, Naber SK, Lansdorp-Vogelaar I, Jenkins MA, Buchanan DD, Preen DB, Ee HC, O'Leary P.

J Gastroenterol Hepatol. 2018 Oct;33(10):1737-1744. doi: 10.1111/jgh.14154. Epub 2018 May 17.

9.

Effect of Cervical Cancer Screening Programs on Preterm Birth: A Decision and Cost-Effectiveness Analysis.

Kamphuis EI, Naber SK, Danhof NA, Habbema JDF, de Groot CJM, Mol BWJ.

Obstet Gynecol. 2017 Dec;130(6):1207-1217. doi: 10.1097/AOG.0000000000002366.

PMID:
29112652
10.

Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer.

Naber SK, Kuntz KM, Henrikson NB, Williams MS, Calonge N, Goddard KAB, Zallen DT, Ganiats TG, Webber EM, Janssens ACJW, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I.

Gastroenterology. 2018 Jan;154(1):105-116.e20. doi: 10.1053/j.gastro.2017.09.021. Epub 2017 Sep 28.

11.

Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study.

Rozemeijer K, Naber SK, Penning C, Overbeek LI, Looman CW, de Kok IM, Matthijsse SM, Rebolj M, van Kemenade FJ, van Ballegooijen M.

BMJ. 2017 Feb 14;356:j504. doi: 10.1136/bmj.j504.

12.

Public Health Benefits of Routine Human Papillomavirus Vaccination for Adults in the Netherlands: A Mathematical Modeling Study.

Matthijsse SM, Hontelez JA, Naber SK, Rozemeijer K, de Kok IM, Bakker R, van Ballegooijen M, van Rosmalen J, de Vlas SJ.

J Infect Dis. 2016 Sep 15;214(6):854-61. doi: 10.1093/infdis/jiw256. Epub 2016 Jun 20.

PMID:
27330051
13.

Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.

Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE, Lansdorp-Vogelaar I, Kuntz KM.

JAMA. 2016 Jun 21;315(23):2595-609. doi: 10.1001/jama.2016.6828.

14.

The role of pre-invasive disease in overdiagnosis: A microsimulation study comparing mass screening for breast cancer and cervical cancer.

van Luijt PA, Rozemeijer K, Naber SK, Heijnsdijk EA, van Rosmalen J, van Ballegooijen M, de Koning HJ.

J Med Screen. 2016 Dec;23(4):210-216. Epub 2016 Apr 11.

PMID:
27068430
15.

The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study.

Naber SK, de Kok IM, Matthijsse SM, van Ballegooijen M.

Cancer Causes Control. 2016 Apr;27(4):569-81. doi: 10.1007/s10552-016-0732-7. Epub 2016 Mar 12.

16.

Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.

Naber SK, Matthijsse SM, Rozemeijer K, Penning C, de Kok IM, van Ballegooijen M.

PLoS One. 2016 Jan 29;11(1):e0145548. doi: 10.1371/journal.pone.0145548. eCollection 2016.

17.

Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening.

O'Mahony JF, Naber SK, Normand C, Sharp L, O'Leary JJ, de Kok IM.

Value Health. 2015 Dec;18(8):1138-51. doi: 10.1016/j.jval.2015.09.2939. Epub 2015 Nov 17. Review. Erratum in: Value Health. 2017 Mar;20(3):517.

18.

Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates.

Rozemeijer K, Penning C, Siebers AG, Naber SK, Matthijsse SM, van Ballegooijen M, van Kemenade FJ, de Kok IM.

Cancer Causes Control. 2016 Jan;27(1):15-25. doi: 10.1007/s10552-015-0678-1. Epub 2015 Oct 12.

19.

The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.

Matthijsse SM, Hontelez JAC, Naber SK, van Rosmalen J, Rozemeijer K, Penning C, Bakker R, van Ballegooijen M, de Kok IMCM, de Vlas SJ.

Vaccine. 2015 Oct 5;33(41):5357-5364. doi: 10.1016/j.vaccine.2015.08.079. Epub 2015 Sep 5.

PMID:
26348405
20.

When is it effective to offer self-sampling to non-attendees--response.

Rozemeijer K, de Kok IM, Naber SK, van Kemenade FJ, Penning C, van Rosmalen J, van Ballegooijen M.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1296. doi: 10.1158/1055-9965.EPI-15-0523. No abstract available.

21.

Exploring the trend of increased cervical intraepithelial neoplasia detection rates in the Netherlands.

Rozemeijer K, van Kemenade FJ, Penning C, Matthijsse SM, Naber SK, van Rosmalen J, van Ballegooijen M, de Kok IM.

J Med Screen. 2015 Sep;22(3):144-50. doi: 10.1177/0969141315580836. Epub 2015 May 14.

PMID:
25977375
22.

Offering Self-Sampling to Non-Attendees of Organized Primary HPV Screening: When Do Harms Outweigh the Benefits?

Rozemeijer K, de Kok IM, Naber SK, van Kemenade FJ, Penning C, van Rosmalen J, van Ballegooijen M.

Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):773-82. doi: 10.1158/1055-9965.EPI-14-0998. Epub 2014 Nov 28.

Supplemental Content

Loading ...
Support Center